LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
Net Income (Common)
LAVA Therapeutics NV
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Net Income (Common)
-$42m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
AEX:PHARM
|
Net Income (Common)
-$10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
Uniqure NV
NASDAQ:QURE
|
Net Income (Common)
-$308.5m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-23%
|
|
argenx SE
XBRU:ARGX
|
Net Income (Common)
-$295.1m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Merus NV
NASDAQ:MRUS
|
Net Income (Common)
-$154.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Net Income (Common)
-€78.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LAVA Therapeutics NV's Net Income (Common)?
Net Income (Common)
-42m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Net Income (Common) amounts to -42m USD.
What is LAVA Therapeutics NV's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-39%
Over the last year, the Net Income (Common) growth was -32%. The average annual Net Income (Common) growth rates for LAVA Therapeutics NV have been -39% over the past three years .